From: biopharmadive.com For the first time, regulators in the U.S., Australia and Canada on Tuesday simultaneously approved two cancer drugs via a project led by the Food and Drug Administration’s oncology center. Merck & Co.’s immunotherapy Keytruda, when paired with Merck and Eisai’s Lenvima, is now cleared to treat certain endometrial tumors, a decision that expands the labels for both …